![]() ![]() PD patients with ≥2 hours per day of OFF time despite oral levodopa ≥4 times per day were randomized to CVT-301 or placebo for 4 weeks, to be used up to 3 times per day for OFF episodes. The objective of this study was to evaluate CVT-301 self-administered by PD patients to relieve OFF episodes. ![]() CVT-301 is a levodopa inhalation powder with the potential for rapid onset of action. Full author disclosures are listed at the end of the article.Īlthough levodopa is the most effective oral PD therapy, many patients experience motor fluctuations, including sudden loss of dose effect and delayed benefit. Fabrizio Stocchi and Aaron Ellenbogen have nothing to report. Kieburtz is a consultant for Acorda and Civitas. Hampson worked as a noncompensated pulmonary consultant to Civitas. Mika Leinonen is a biostatistician at 4Pharma AB, a contract research organization that provided compensated statistical consultation services to Civitas and Acorda. Marie-Helene Saint-Hilaire's institution has received clinical research grants from Civitas. ![]() Grosset received compensation for consulting services to Civitas. Hauser's institution has received research support from Civitas. LeWitt has served as a consultant for Acorda and the Parkinson's Disease and Movement Disorders Program that he directs has received clinical research grant support (for conducting clinical trials) from Acorda. Relevant conflicts of interest/financial disclosures: Peter A. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |